Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896675 · ClinicalTrials.gov registry record
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
A clinical trial of Head and Neck Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 352
- Enrollment target
- 3
- Study locations
NCT00896675: Completed study of Head and Neck Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00896675 is a study of Head and Neck Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 352 participants, above the 259-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (36% higher). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00896675, a study of Head and Neck Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 352 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at proteins in blood samples to predict treatment benefit in patients with recurrent and/or metastatic squamous cell head and neck cancer.
Conditions Studied
Interventions
- OTHER proteomic profiles
Study Locations (3)
Tennessee
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- Vanderbilt-Ingram Cancer Center at Franklin - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-12 |
What the finished NCT00896675 record still lists
NCT00896675 is an observational study that tracks outcomes without assigning an intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, above the 259-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (36% higher).
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which proteomic profiles is the first listed.
NCT00896675 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00896675 about?
NCT00896675 is a clinical study titled "Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer". RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at proteins in blood samples to predict treatment benefit in patients with recurrent...
What is the current status of trial NCT00896675?
This trial is currently completed. The enrollment target is 352 participants. The study started on 2007-06. Estimated completion is 2009-12.
What conditions does trial NCT00896675 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT00896675?
The interventions under investigation include: proteomic profiles (OTHER).
Who is sponsoring clinical trial NCT00896675?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00896675 being conducted?
This trial has 3 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00896675's enrollment target sits among peer trials
352 27th of 250 higher than 223 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3D Specimen Maps for RT Planning
RECRUITING
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck
RECRUITING · NA
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
- NCT07011732 · 352 participants · Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia